Journal Home > Volume 9 , Issue 1

COVID-19 has been an emerging and rapidly evolving risk to people of the world in 2020. Facing this dangerous situation, many colleagues in Neurorestoratology did their best to avoid infection if themselves and their patients, and continued their work in the research areas described in the 2020 Yearbook of Neurorestoratology. Neurorestorative achievements and progress during 2020 includes recent findings on the pathogenesis of neurological diseases, neurorestorative mechanisms and clinical therapeutic achievements. Therapeutic progress during this year included advances in cell therapies, neurostimulation/neuromodulation, brain-computer interface (BCI), and pharmaceutical neurorestorative therapies, which improved neurological functions and quality of life for patients. Four clinical guidelines or standards of Neurorestoratology were published in 2020. Milestone examples include: 1) a multicenter randomized, double-blind, placebo-controlled study of olfactory ensheathing cell treatment of chronic stroke showed functional improvements; 2) patients after transhumeral amputation experienced increased sensory acuity and had improved effectiveness in work and other activities of daily life using a prosthesis; 3) a patient with amyotrophic lateral sclerosis used a steady-state visual evoked potential (SSVEP)-based BCI to achieve accurate and speedy computer input; 4) a patient with complete chronic spinal cord injury recovered both motor function and touch sensation with a BCI and restored ability to detect objects by touch and several sensorimotor functions. We hope these achievements motivate and encourage other scientists and physicians to increase neurorestorative research and its therapeutic applications.


menu
Abstract
Full text
Outline
About this article

The 2020 Yearbook of Neurorestoratology

Show Author's information Hongyun Huang1( )Lin Chen2Michael Chopp3,4Wise Young5John Robert Bach6Xijing He7Anna Sarnowaska8Mengzhou Xue9Robert Chunhua Zhao10Ashok Shetty11Dario Siniscalco12Xiaoling Guo13Alireza Khoshnevisan14Ziad Hawamdeh15
Beijing Hongtianji Neuroscience Academy, Beijing 100143, China
Department of Neurosurgery, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine Beijing, Beijing 100007, China
Department of Neurology, Henry Ford Hospital, Detroit, MI, USA
Department of Physics, Oakland University, Rochester, MI, USA
Department of Cell Biochemistry and Neuroscience, Rutgers University, New Jersey, USA
Center for Ventilator Management Alternatives, University Hospital, Newark, New Jersey, USA
Department of Orthopedics, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, Shaanxi, China
Translational Platform for Regenerative Medicine & Cell Therapy Team of The Central Nervous System Diseases, Polish Academy of Sciences, Warsaw, Poland
The Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Henan Joint International Laboratory of Intracerebral Hemorrhagic Brain Injury, Zhengzhou 450001, Henan, China
Center of Excellence in Tissue Engineering, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of New Drug Development and Clinical Trial of Stem Cell Therapy, Beijing 100005, China
Institute for Regenerative Medicine, Department of Molecular and Cellular Medicine, College of Medicine, Texas A&M University, USA
Department of Experimental Medicine, University of Campania "Luigi Vanvitelli" via S. Maria di Costantinopoli 16 80138 Naples, Italy
Neurological Center, The 981 Hospital of PLA, Chengde 067000, Hebei, China
School of Medicine, The University of Jordan, Amman, Jordan
Department of Neurosurgery, Tehran University of Medical Sciences, Tehran, Iran

Abstract

COVID-19 has been an emerging and rapidly evolving risk to people of the world in 2020. Facing this dangerous situation, many colleagues in Neurorestoratology did their best to avoid infection if themselves and their patients, and continued their work in the research areas described in the 2020 Yearbook of Neurorestoratology. Neurorestorative achievements and progress during 2020 includes recent findings on the pathogenesis of neurological diseases, neurorestorative mechanisms and clinical therapeutic achievements. Therapeutic progress during this year included advances in cell therapies, neurostimulation/neuromodulation, brain-computer interface (BCI), and pharmaceutical neurorestorative therapies, which improved neurological functions and quality of life for patients. Four clinical guidelines or standards of Neurorestoratology were published in 2020. Milestone examples include: 1) a multicenter randomized, double-blind, placebo-controlled study of olfactory ensheathing cell treatment of chronic stroke showed functional improvements; 2) patients after transhumeral amputation experienced increased sensory acuity and had improved effectiveness in work and other activities of daily life using a prosthesis; 3) a patient with amyotrophic lateral sclerosis used a steady-state visual evoked potential (SSVEP)-based BCI to achieve accurate and speedy computer input; 4) a patient with complete chronic spinal cord injury recovered both motor function and touch sensation with a BCI and restored ability to detect objects by touch and several sensorimotor functions. We hope these achievements motivate and encourage other scientists and physicians to increase neurorestorative research and its therapeutic applications.

Keywords: Neurorestoratology, yearbook, pathogenesis, neurorestorative mechanism, therapeutic achievement, guidelines, standards

References(82)

[1]
Friker LL, Scheiblich H, Hochheiser IV, et al. β-amyloid clustering around ASC fibrils boosts its toxicity in microglia. Cell Rep 2020, 30(11): 3743-3754.e6.
[2]
Chun H, Im H, Kang YJ, et al. Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer's disease via H2O2-production. Nat Neurosci 2020, 23(12): 1555-1566.
[3]
Winer JR, Mander BA, Kumar S, et al. Sleep disturbance forecasts β-amyloid accumulation across subsequent years. Curr Biol 2020, 30(21): 4291-4298.e3.
[4]
Qian H, Kang XJ, Hu J, et al. Reversing a model of Parkinson's disease with in situ converted nigral neurons. Nature 2020, 582(7813): 550-556.
[5]
Zhou HB, Su JL, Hu XD, et al. Glia-to-neuron conversion by CRISPR-CasRx alleviates symptoms of neurological disease in mice. Cell 2020, 181(3): 590-603.e16.
[6]
Giacomoni J, Bruzelius A, Stamouli CA, et al. Direct conversion of human stem cell-derived glial progenitor cells into GABAergic interneurons. Cells 2020, 9(11): E2451.
[7]
Nolbrant S, Giacomoni J, Hoban DB, et al. Direct reprogramming of human fetal- and stem cell-derived glial progenitor cells into midbrain dopaminergic neurons. Stem Cell Reports 2020, 15(4): 869-882.
[8]
Serapide MF, L'Episcopo F, Tirolo C, et al. Boosting antioxidant self-defenses by grafting astrocytes rejuvenates the aged microenvironment and mitigates nigrostriatal toxicity in parkinsonian brain via an Nrf2-driven wnt/β-catenin prosurvival axis. Front Aging Neurosci 2020, 12: 24.
[9]
Marchetti B, Tirolo C, L'Episcopo F, et al. Parkinson's disease, aging and adult neurogenesis: Wnt/β-catenin signalling as the key to unlock the mystery of endogenous brain repair. Aging Cell 2020, 19(3): e13101.
[10]
Liraz-Zaltsman S, Friedman Levi Y, Shabashov- Stone D, et al. Chemokine receptors CC chemokine receptor 5 and C-X-C motif chemokine receptor 4 are new therapeutic targets for brain recovery after traumatic brain injury. J Neurotrauma 2021, in press, .
[11]
Hur JY, Frost GR, Wu X, et al. The innate immunity protein IFITM3 modulates γ-secretase in Alzheimer's disease. Nature 2020, 586(7831): 735-740.
[12]
Krukowski K, Nolan A, Frias ES, et al. Small molecule cognitive enhancer reverses age-related memory decline in mice. Elife 2020, 9: e62048.
[13]
Lu YC, Brommer B, Tian X, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature 2020, 588(7836): 124-129.
[14]
Zhou X, Wahane S, Friedl MS, et al. Microglia and macrophages promote corralling, wound compaction and recovery after spinal cord injury via Plexin-B2. Nat Neurosci 2020, 23(3): 337-350.
[15]
Chen YF, Li J, Ma BT, et al. MSC-derived exosomes promote recovery from traumatic brain injury via microglia/macrophages in rat. Aging (Albany NY) 2020, 12(18): 18274-18296.
[16]
Wang YL, Guo XL, Liu J, et al. Olfactory ensheathing cells in chronic ischemic stroke: A phase 2 double-blind, randomized, controlled trial. J Neurorestoratology 2020, 8(3): 182-193.
[17]
Muir KW, Bulters D, Willmot M, et al. Intracerebral implantation of human neural stem cells and motor recovery after stroke: multicentre prospective single-arm study (PISCES-2). J Neurol Neurosurg Psychiatry 2020, 91(4): 396-401.
[18]
Steinberg GK, Kondziolka D, Wechsler LR, et al. Clinical outcomes of transplanted modified bone marrow-derived mesenchymal stem cells in stroke: a phase 1/2a study. Stroke 2016, 47(7): 1817-1824.
[19]
Steinberg GK, Kondziolka D, Wechsler LR.et al. Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (SB623): a phase 1/2a study. J Neurosurg 2018, 1: 1-11.
[20]
SanBio Co. Ltd. SanBio and Sumitomo Dainippon Pharma announce topline results from a phase 2b study in the U.S. Evaluating SB623, a regenerative cell medicine for the treatment of patients with chronic stroke. Available at https://www.ds-pharma.com/ir/news/pdf/ene20190129.1.pdf.
[21]
Schweitzer JS, Song B, Herrington TM, et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson's disease. N Engl J Med 2020, 382(20): 1926-1932.
[22]
Liem NT, Chinh VD, Phuong DTM, et al. Outcomes of bone marrow-derived mononuclear cell transplantation for patients in persistent vegetative state after drowning: report of five cases. Front Pediatr 2020, 8: 564.
[23]
Liem NT, Huyen TL, Huong LT, et al. Outcomes of bone marrow mononuclear cell transplantation for neurological sequelae due to intracranial hemorrhage incidence in the neonatal period: report of four cases. Front Pediatr 2019, 7: 543.
[24]
Yang Y, Pang M, Du C, et al. Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: a phase 1/2 pilot study. Cytotherapy 2021, 23(1): 57-64.
[25]
Berry JD, Cudkowicz ME, Windebank AJ, et al. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results. Neurology 2019, 93(24): e2294-e2305.
[26]
Beauchamp MS, Oswalt D, Sun P, et al. Dynamic stimulation of visual cortex produces form vision in sighted and blind humans. Cell 2020, 181(4): 774-783.e5.
[27]
Shi NL. Steady-state visual evoked potential (SSVEP)-based brain-computer interface (BCI) of Chinese speller for a patient with amyotrophic lateral sclerosis: a case report. J Neurorestoratology 2020, 8(1): 40-52.
[28]
Ortiz-Catalan M, Mastinu E, Sassu P, et al. Self-contained neuromusculoskeletal arm prostheses. N Engl J Med 2020, 382(18): 1732-1738.
[29]
Mastinu E, Engels LF, Clemente F, et al. Neural feedback strategies to improve grasping coordination in neuromusculoskeletal prostheses. Sci Rep 2020, 10(1): 11793.
[30]
Middleton A, Ortiz-Catalan M. Neuromusculoskeletal arm prostheses: personal and social implications of living with an intimately integrated bionic arm. Front Neurorobot 2020, 14: 39.
[31]
Schofield JS, Shell CE, Beckler DT, et al. Long-term home-use of sensory-motor-integrated bidirectional bionic prosthetic arms promotes functional, perceptual, and cognitive changes. Front Neurosci 2020, 14: 120.
[32]
Ganzer PD, Colachis SC 4th, Schwemmer MA, et al. Restoring the sense of touch using a sensorimotor demultiplexing neural interface. Cell 2020, 181(4): 763-773.e12.
[33]
Stabingas K, Bergman J, Patterson M, et al. Peripheral subcutaneous field stimulation for the treatment of spinal cord injury at-level pain: case report, literature review, and 5-year follow-up. Heliyon 2020, 6(7): e04515.
[34]
Li LM. Special issue on vagus nerve stimulation and spinal cord stimulation. J Neurorestoratology 2020, 8(3): 131.
[35]
Gill M, Linde M, Fautsch K, et al. Epidural electrical electrical stimulation of the lumbosacral spinal cord improves trunk stability during seated reaching in two humans with severe thoracic spinal cord Injury. Front Syst Neurosci 2020, 14: 79.
[36]
Peña Pino I, Hoover C, Venkatesh S, et al. Long-term spinal cord stimulation after chronic complete spinal cord injury enables volitional movement in the absence of stimulation. Front Syst Neurosci 2020, 14: 35.
[37]
Shah-Basak PP, Sivaratnam G, Teti S, et al. High definition transcranial direct current stimulation modulates abnormal neurophysiological activity in post-stroke aphasia. Sci Rep 2020, 10(1): 19625.
[38]
Campanella W, Pedrini R, Vestito L, et al. Transcranial direct current stimulation in the treatment of subacute post-stroke thalamic aphasia. Eur J Case Rep Intern Med 2020, 7(11): 001794.
[39]
Ihara AS, Miyazaki A, Izawa Y, et al. Enhancement of facilitation training for aphasia by transcranial direct current stimulation. Front Hum Neurosci 2020, 14: 573459.
[40]
Sebastian R, Kim JH, Brenowitz R, et al. Cerebellar neuromodulation improves Naming in post-stroke aphasia. Brain Commun 2020, 2(2): fcaa179.
[41]
Unal G, Ficek B, Webster K, et al. Impact of brain atrophy on tDCS and HD-tDCS current flow: a modeling study in three variants of primary progressive aphasia. Neurol Sci 2020, 41(7): 1781-1789.
[42]
Garcia S, Hampstead BM. HD-tDCS as a neurorehabilitation technique for a case of post-anoxic leukoencephalopathy. Neuropsychol Rehabil 2020: 1-21.
[43]
Zhang R, Zhang LP, Guo YK, et al. Effects of high-definition transcranial direct-current stimulation on resting-state functional connectivity in patients with disorders of consciousness. Front Hum Neurosci 2020, 14: 560586.
[44]
Wang X, Guo Y, Zhang Y, et al. Combined behavioral and mismatch negativity evidence for the effects of long-lasting high-definition tDCS in disorders of consciousness: a pilot study. Front Neurosci 2020, 14: 381
[45]
Qiao YX, Hu Q, Xuan RR, et al. High-definition transcranial direct current stimulation facilitates emotional face processing in individuals with high autistic traits: a sham-controlled study. Neurosci Lett 2020, 738: 135396.
[46]
Thimmashetty VH, Parlikar R, Selvaraj S, et al. Target specific effects of direct current stimulation in schizo-obsessive disorder: a case report. Brain Stimul 2020, 13(3): 858-860.
[47]
Khaleghi A, Pirzad Jahromi G, Zarafshan H, et al. Effects of transcranial direct current stimulation of prefrontal cortex on risk-taking behavior. Psychiatry Clin Neurosci 2020, 74(9): 455-465.
[48]
Li F, Ball S, Zhang X, et al. Focal stimulation of the temporoparietal junction improves rationality in prosocial decision-making. Sci Rep 2020, 10(1): 20275.
[49]
Ma YB, Yin KY, Zhuang W, et al. Effects of combining high-definition transcranial direct current stimulation with short-foot exercise on chronic ankle instability: a pilot randomized and double-blinded study. Brain Sci 2020, 10(10): 749.
[50]
Lu JC, Feng ZH, Shi X, et al. Correlation between programmed stimulation parameters and their efficacy after deep brain electrode implantation for Parkinson's disease. J Neurorestoratology 2020, 8(1): 53-59.
[51]
Badhiwala JH, Wilson JR, Witiw CD, et al. The influence of timing of surgical decompression for acute spinal cord injury: a pooled analysis of individual patient data. Lancet Neurol 2021, 20(2): 117-126.
[52]
Yamawaki R, Nankaku M, Ikeguchi R, et al. Finger sensory impairment after elbow flexion reconstruction using concomitant nerve transfer from the Median and ulnar nerves. Somatosens Mot Res 2020, 37(4): 233-237.
[53]
Huang AE, Noland SS, Spinner RJ, et al. Outcomes of reconstructive surgery in traumatic brachial plexus injury with concomitant vascular injury. World Neurosurg 2020, 135: e350-e357.
[54]
Pages L, Le Hanneur M, Cambon-Binder A, et al. C5/C6 brachial plexus palsy reconstruction using nerve surgery: long-term functional outcomes. Orthop Traumatol Surg Res 2020, 106(6): 1095-1100.
[55]
Bhatia A, Kulkarni A, Zancolli P, et al. The effect of age and the delay before surgery on the outcomes of intercostal nerve transfers to the musculocutaneous nerve: a retrospective study of 232 cases of posttraumatic total and near-total brachial plexus injuries. Indian J Plast Surg 2020, 53(2): 260-265.
[56]
Lara AM, Bhatia A, Correa JC, et al. Intercostal nerve transfers to the musculocutaneous-A reliable nerve transfer for restoration of elbow flexion in birth-related brachial plexus injuries. Indian J Plast Surg 2020, 53(2): 254-259.
[57]
Kang GH, Lim RQ, Yong FC. Elbow flexion reconstruction in brachial plexus avulsion injuries - results with intercostal nerve and distal nerve transfers. J Hand Surg Asian Pac Vol 2020, 25(3): 307-314.
[58]
Hajjar I, Okafor M, McDaniel D, et al. Effects of candesartan vs lisinopril on neurocognitive function in older adults with executive mild cognitive impairment. JAMA Netw Open 2020, 3(8): e2012252.
[59]
Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement 2020 17(4): 696-701.
[60]
Hill MD, Goyal M, Menon BK, et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet 2020, 395(10227): 878-887.
[61]
AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2020, 19(8): 651-660.
[62]
EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo- controlled trial. Lancet Neurol 2020, 19(8): 661-669.
[63]
Dennis M, Forbes J, Graham C, et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technol Assess 2020, 24(22): 1-94.
[64]
Mullard A. Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating. Nat Rev Drug Discov 2021, 20(1): 3-5.
[65]
Honjo Y, Ide K, Takechi H. Medical interventions suppressed progression of advanced Alzheimer's disease more than mild Alzheimer's disease. Geriatr Gerontol Int 2020, 20(4): 324-328.
[66]
Ton AMM, Campagnaro BP, Alves GA, et al. Oxidative stress and dementia in Alzheimer's patients: effects of synbiotic supplementation. Oxid Med Cell Longev 2020, 2020: 2638703.
[67]
Villar-Martínez MD, Moreno-Ajona D, Goadsby PJ. Eptinezumab for the preventive treatment of migraine. Pain Manag 2021, 11(2): 113-121.
[68]
Graf J, Albrecht P, Goebels N, et al. Erratum to: Ocrelizumab for treatment of multiple sclerosis. Nervenarzt 2020, 91(8): 735-736.
[69]
Nutt JG, Curtze C, Hiller A, et al. Aromatic L-amino acid decarboxylase gene therapy enhances levodopa response in Parkinson's disease. Mov Disord 2020, 35(5): 851-858.
[70]
Chu YP, Bartus RT, Manfredsson FP, et al. Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease. Brain 2020, 143(3): 960-975.
[71]
Castle MJ, Baltanás FC, Kovacs I, et al. Postmortem analysis in a clinical trial of AAV2-NGF gene therapy for Alzheimer's disease identifies a need for improved vector delivery. Hum Gene Ther 2020, 31(7/8): 415-422.
[72]
Li T, Sui Z, Matsuno A, et al. Fabrication and evaluation of a xenogeneic decellularized nerve- derived material: preclinical studies of a new strategy for nerve repair. Neurotherapeutics 2020, 17(1): 356-370.
[73]
Honjo Y, Ide K, Takechi H. Use of day services improved cognitive function in patients with Alzheimer's disease. Psychogeriatrics 2020, 20(5): 620-624.
[74]
Andreassen M, Hemmingsson H, Boman IL, et al. Feasibility of an intervention for patients with cognitive impairment using an interactive digital calendar with mobile phone reminders (RemindMe) to improve the performance of activities in everyday life. Int J Environ Res Public Health 2020, 17(7): E2222.
[75]
Hachmo Y, Hadanny A, Abu Hamed R, et al. Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trial. Aging (Albany NY) 2020, 12(22): 22445-22456.
[76]
Morin CM, Edinger JD, Beaulieu-Bonneau S, et al. Effectiveness of sequential psychological and medication therapies for insomnia disorder: a randomized clinical trial. JAMA Psychiatry 2020, 77(11): 1-9.
[77]
Herrity AN, Aslan SC, Ugiliweneza B, et al. Improvements in bladder function following activity-based recovery training with epidural stimulation after chronic spinal cord injury. Front Syst Neurosci 2020, 14: 614691.
[78]
Krucoff MO, Gramer R, Lott D, et al. Spinal cord stimulation and rehabilitation in an individual with chronic complete L1 paraplegia due to a conus medullaris injury: motor and functional outcomes at 18 months. Spinal Cord Ser Cases 2020, 6(1): 96.
[79]
Guo XL, Xue Q, Zhao JH, et al. Clinical diagnostic and therapeutic guidelines of stroke neurorestoration (2020 China version). J Neurorestoratology 2020, 8(4): 241-251.
[80]
Chen L, Chen T, Mao GS, et al. Clinical neurorestorative therapeutic guideline for brainstem hemorrhage (2020 China version). J Neurorestoratology 2020, 8(4): 232-240.
[81]
Huang HY, Gao WY, Yan ZH, et al. Standards of clinical-grade olfactory ensheathing cell culture and quality control (2020 China version). J Neurorestoratology 2020, 8(4): 217-231.
[82]
Xiang SL, Gao WY, Peng HN, et al. Standards of clinical-grade mesenchymal stromal cell preparation and quality control (2020 China version). J Neurorestoratology 2020, 8(4): 197-216.
Publication history
Copyright
Rights and permissions

Publication history

Received: 26 February 2021
Revised: 18 March 2021
Accepted: 19 March 2021
Published: 08 June 2021
Issue date: March 2021

Copyright

© The authors 2021

Rights and permissions

This article is published with open access at http://jnr.tsinghuajournals.com

Return